Imara Inc. was a Boston-based clinical-stage biopharmaceutical company dedicated to developing novel therapeutics for sickle cell disease and beta-thalassemia. Founded in 2016, Imara advanced its lead candidate tovinontrine through clinical trials before discontinuing the program in 2022. The company subsequently completed a reverse merger with Enliven Therapeutics in February 2023.
Create a free account to see funding visualizations and detailed round data.
Create Free AccountCreate a free account to see full funding history, valuations, and investor participation.
Create Free AccountCreate a free account to see which investors have funded this company.
Create Free Account